抄録
T-1220 was evaluated on 10 patients : 4 patients with septicemia, 1 patient with fever after pacemaker implantation, 1 patient with purulent peritonitis, 3 patients with respiratory infection and 1 patient with pyelonephritis.
The clinical responses were considered to be satisfactory except 1 patients with Pseudomonas septicemia and lung cancer. Two patients experienced skin rash in the course of the treatment. A patient who received 291 gram of T-1220 of total dose experienced anemia in moderate degree.
